Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 9 and last traded at GBX 9, with a volume of 312497 shares trading hands. The stock had previously closed at GBX 8.50.
Allergy Therapeutics Stock Performance
The company has a fifty day moving average price of GBX 8.22 and a 200 day moving average price of GBX 7.79. The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. The stock has a market cap of £536.15 million, a PE ratio of -12.13, a P/E/G ratio of -30.70 and a beta of 1.40.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- Market Cap Calculator: How to Calculate Market Cap
- Netflix Stock Split Explained: What It Means for Investors
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- SoundHound Beat Earnings & Dropped—Here’s What Wall Street Missed
- How to Invest in Biotech Stocks
- AI Trade Over? Datadog Results Say It’s Gaining Momentum
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
